US academic health centers are increasingly investing through venture capital in biotechnology and health innovation. Between 2010 and 2023, these centers have collectively invested more than $1.2 billion in 160 companies. They most often invested in the fields of oncology, neuroscience and genetics. More than half of the investments were focused on early-stage companies. The average investment per company was $7.5 million. Most of the investments were made through own funds or joint ventures with external investors. The goal is to support the transfer of research results into practice and the development of new treatment methods.